To investigate the genetic diversity of porcine reproductive and respiratory syndrome virus (PRRSV) in Northern Ireland, the ORF5 gene from nine field isolates was sequenced and phylogenetically analysed. The results revealed relatively high diversity amongst isolates, with 87.6-92.2% identity between farms at the nucleotide level and 84.1-93.5% identity at the protein level. Phylogenetic analysis confirmed that all nine isolates belonged to the European (type 1) genotype and formed a cluster within the subtype 1 subgroup. This study provides the first report on PRRSV isolate diversity in Northern Ireland.
Porcine reproductive and respiratory syndrome virus (PRRSV), the causative agent of porcine reproductive and respiratory syndrome (PRRS), is a small, enveloped, positive-sense, single-stranded RNA virus belonging to the genus Arterivirus. It is responsible for inducing reproductive failure in sows and respiratory disease in growing pigs [1] . Two genotypes of PRRSV are recognised internationally: European (type 1) and North American (type 2). The type 2 virus was originally isolated in pig herds in America in 1987 [2] , while type 1 was first identified in European pigs in 1991 [3] . Although the first outbreaks occurred close together, the two genotypes have high sequence divergence and share only 50-70% genetic identity [4] [5] [6] [7] . There are at least four subtypes of type 1 PRRSV, with different worldwide and European distributions as well as variations in pathogenicity [8] . Similarly, type 2 PRRSV is further divided into several lineages [9] .
The high strain diversity of PRRSV is consistent with that of other RNA viruses, and this results in rapidly emerging virus variants that lead to recurrent disease outbreaks and increased difficulty with virus control [10] [11] [12] . As the island of Ireland is geographically isolated, we hypothesised that Northern Ireland (NI) may have circulating strains of virus that are different from those found in Great Britain and the rest of Europe. The genotype of the virus has obvious implications for diagnostics and vaccination, with only limited protection afforded against heterologous strains. In this study, the ORF5 gene from PRRSV field isolates in NI was sequenced and compared with those from modified live virus (MLV) vaccine sequences and other European isolates. The genetic diversity of PRRSV strains in NI relative to vaccine and European wild-type strains was examined, and the implications for PRRSV-associated disease management are discussed.
Seven lung samples and two mesenteric lymph node (MLN) samples were obtained from nine pigs from five farms in NI. Ten percent w/v tissue homogenates were prepared, and RNA was extracted using standard methods. A previously described primer set [13] was used to amplify a 780-bp PCR product containing the complete ORF5 gene of PRRSV, and resultant amplicons were sequenced commercially. Raw sequence reads were analysed and trimmed using Geneious version 6 [14] . Clustal W was used to align the NI nucleotide sequences with a selection of chronologically and geographically varied wild-type PRRSV type 1 isolates from subtypes 1-4 as well as MLV sequences from GenBank. Phylogenetic trees were generated using the neighbour-joining method [15] in MEGA 6 [16] with 1000 iterations for bootstrapping. Predicted protein sequences were also aligned using Clustal W. The sequences of the predicted GP5 proteins were searched for motifs associated Handling Editor: Zhenhai Chen.
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with N-linked glycosylation [17] and a previously described neutralising epitope [18, 19] .
All field isolates from NI were analysed and confirmed as type 1 4) . NI sequences were also compared to the ORF5 sequences of four commercially available PRRSV MLV vaccines. Sequence comparison showed nucleotide sequence identity ranging from 84.7-92.9%. The majority of NI PRRSV isolates were collected in 2015 (eight sequences from four farms), and these clustered together as a distinct subtype 1 subgroup on the phylogenetic tree as part of a larger subgroup (Fig. 1) . One sequence from farm 13320-12, collected in 2012, clustered with UK and North American strains, most closely clustering with EuroPRSSV (accession no. AY366525) [20] .
The predicted proteins were 201 amino acids in length for all NI sequences, with sequence identity to the other international sequences ranging from 74.1 to 100% (Table 1) , reflecting the differences evident at the nucleotide level. NI PRRSV protein sequences were 81.6-91.5% identical to vaccine strains.
The presence of a neutralisation epitope located in the N-terminus of the GP5 ectodomain was observed between residues 29 and 35 (WSFADGN) (Fig. 2) , as described previously [19] . The MLV vaccine-derived sequences and three other subtype 1 sequences had a slightly different motif of WSFVDGN. Interestingly, the two NI sequences from farm 1776-15 had differences in the neutralisation epitope at residues 30 and 35, resulting in a motif of WPFADGA. All ORF5 sequences displayed three potential N-linked glycosylation sites, at residues 37-39 (Asn-Ser-Ser), 46-48 (AsnLeu-Ser) and 53-55 (Asn-Gly-Thr). One NI sequence from farm 5612-15 displayed an additional N-linked glycosylation site at residues 38-40 (Asn-Ser-Thr), which overlapped with the sequon at residues 37-39 to contain the sequence Asn-Asn-Ser-Thr.
ORF5 was targeted for phylogenetic analysis as it encodes the most variable structural protein, GP5 [13, 21] . GP5 is also the major target for virus-neutralising antibodies [22] and, as such, is important in relation to protection derived from previous infection or vaccination. Alignment of the complete ORF5 sequences revealed nucleotide sequence identity ranging from 87.6 to 100% between NI field strains. The sequence variability between these virus strains is consistent with the genetic diversity previously reported for PRRSV isolates in the United Kingdom [23], Italy [13] , Denmark [24] , the United States [6] , China [25] and Poland [26] . Phylogenetic analysis confirmed that all NI PRRSV isolates are of the European genotype and placed the 2015 NI sequences into a distinct cluster within this group (Fig. 1) . As expected, virus sequences from the same farms were closely related.
Interestingly, sequence diversity was observed between the ORF5 nucleotide and predicted protein sequences of circulating NI isolates and those of MLV vaccine sequences. This suggests that vaccine efficacy may be compromised in NI. However, further studies are evidently required to determine the significance of these amino acid changes on vaccine efficacy.
As well as resulting in variation in neutralising epitopes, genetic variation can lead to changes in N-linked glycosylation sites, and this can have an effect on the recognition of the neutralisation epitope [32] . Three potential N-linked glycosylation sites were identified in the GP5 ectodomain of NI PRRSV strains at residues 37-39, 46-48 and 53-55. This is consistent with the findings of Pesente et al. [13] and Frossard et al. [23] , who identified the same predicted glycosylation sites on the GP5 protein of Italian and British PRRSV isolates, respectively. Interestingly, in one NI PRRSV strain, an additional N-linked glycosylation site that overlapped with the sequon present at residue 37 was identified. Glycosylation of the viral envelope protein is a mechanism for immune evasion, and several studies have demonstrated a role for PRRSV GP5 glycosylation modification in evading host immune responses [33, 34] . Indeed, removal of N-glycosylation sites surrounding the neutralisation epitope of PRRSV GP5 has been shown to result in increased sensitivity to neutralising antibodies [33] and convalescent-phase serum [17] . Consistent with the NI strains, the majority of subtype 1 sequences studied had predicted N-glycosylation sites at residues 37-39, 46-48 and 53-55. Importantly, all but one of the MLV vaccine strains (Porcilis) had no predicted N-glycosylation at residues 37-39, suggesting that the neutralising epitope may be more immunogenic for these vaccine strains. The presence of N-glycosylation at this site in the NI field isolates could compromise the immunity provided by the vaccines.
In conclusion, despite the genetic diversity observed between NI PRRSV isolates, these strains mostly clustered together in a distinct group within the European genotype. These data demonstrated relatively high genetic variability among PRRSV strains in NI, and this variability poses significant challenges to the control of PRRS through vaccination. The geographical isolation of the island of Ireland may be a positive factor in terms of prevention of the introduction of diverse strains of PRRSV. However, the diversity between Northern Irish PRRSV strains evident in this study suggests that a more in-depth surveillance on an all-island basis will be important in understanding, and locally controlling, PRRSV disease in Ireland. 
